Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:35:21 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:QURE - UNIQURE N.V. - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
QURE - Q3.24.61·6.630.24.67-0.04-0.8547.82,3573,7924.71  4.75  4.6122.48  4.609916:17:45Feb 2815 min RT 2¢

Recent Trades - Last 10 of 3792
Time ETExPriceChangeVolume
16:17:45Q4.67-0.0439,288
16:05:20Q4.61-0.101
16:01:55Q4.67-0.0478
16:01:43Q4.67-0.043,179
16:00:04Q4.67-0.04113
16:00:03Q4.67-0.04819
16:00:03Q4.67-0.043
16:00:03Q4.67-0.04283
16:00:02Q4.67-0.0434
16:00:01Q4.67-0.041,817

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-02-28 07:05U:QURENews ReleaseuniQure Announces 2023 Financial Results and Highlights Recent Company Progress
2023-12-19 07:05U:QURENews ReleaseuniQure Announces Update on Phase I/II Clinical Trials of AMT-130 ‚  Gene Therapy for the Treatment of Huntington ¢ € ™s Disease
2023-12-11 19:30U:QURENews ReleaseCSL Behring's HEMGENIX ‚ ® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
2023-12-08 07:05U:QURENews ReleaseuniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-29 07:05U:QURENews ReleaseuniQure Announces FDA Clearance of Investigational New Drug Application for ‚  AMT-191 Gene Therapy for Fabry Disease
2023-11-07 07:05U:QURENews ReleaseuniQure Announces Third Quarter 2023 Financial Results ‚  and Highlights Recent Company Progress
2023-10-27 10:00U:QURENews ReleaseCSL and uniQure Win 2023 Prix Galien USA Award
2023-10-26 14:14U:QURENews ReleaseHealth Canada Authorizes CSL's HEMGENIX ® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
2023-10-24 07:05U:QURENews ReleaseuniQure Announces Major Presence at the ‚  European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
2023-10-05 07:05U:QURENews ReleaseuniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
2023-10-02 07:05U:QURENews ReleaseuniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-05 07:05U:QURENews ReleaseuniQure Announces FDA Clearance of Investigational New Drug Application for ‚  AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
2023-08-01 07:05U:QURENews ReleaseuniQure Announces Second Quarter 2023 Financial Results ‚  and Highlights Recent Company Progress
2023-06-26 07:12U:QURENews ReleaseuniQure Announces Leadership Addition to Support Advancement of Clinical Programs
2023-06-21 07:05U:QURENews ReleaseuniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 ‚  Gene Therapy for the Treatment of Huntington ¢ € ™s Disease
2023-06-20 07:05U:QURENews ReleaseuniQure announces achievement of $100 million milestone ‚  related to hemophilia B gene therapy
2023-06-20 07:00U:QURENews ReleaseCSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX ‚ ® (etranacogene dezaparvovec-drlb) for Hemophilia B
2023-06-16 07:05U:QURENews ReleaseuniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-15 07:05U:QURENews ReleaseuniQure Announces Sale of Royalty Interest in HEMGENIX ‚ ® for Up To $400 Million
2023-05-09 07:05U:QURENews ReleaseuniQure Announces First Quarter 2023 Financial Results ‚  and Highlights Recent Company Progress